<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180453</url>
  </required_header>
  <id_info>
    <org_study_id>02-350</org_study_id>
    <nct_id>NCT00180453</nct_id>
  </id_info>
  <brief_title>SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System</brief_title>
  <official_title>SPIRIT First: A Clinical Evaluation of an Investigational Device. The Abbott XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial.&#xD;
&#xD;
      Test arm: XIENCE V® Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter:&#xD;
      3.0mm) Control arm: Metallic stent (MULTI-LINK VISION® metallic stent(stent length: 18mm,&#xD;
      diameter: 3.0mm) Follow-up angiographic imaging and intra vascular ultra sound (IVUS) at 180&#xD;
      days and 1 year&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SPIRIT FIRST clinical trial will enroll approximately 60 patients and will assess the&#xD;
      feasibility and performance of the XIENCE V® Everolimus Eluting Coronary Stent System in the&#xD;
      treatment of patients with de novo native coronary artery lesions. In this trial, the XIENCE&#xD;
      V® Everolimus Eluting Coronary Stent System will be compared to the MULTI-LINK VISION®&#xD;
      metallic stent which is CE marked and FDA approved and is available for commercial use in&#xD;
      Europe and in the United States. The SPIRIT FIRST Clinical trial will enroll approximately 60&#xD;
      patients (30 patients in the test arm and 30 patients in the control arm) with de novo native&#xD;
      coronary artery lesions in 4 clinical sites in The Netherlands and Germany&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late loss</measure>
    <time_frame>at 180 days post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent late loss</measure>
    <time_frame>at 1 year post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Loss</measure>
    <time_frame>at 180 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment %Volume Obstruction</measure>
    <time_frame>at 180 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment %Diameter Stenosis</measure>
    <time_frame>at 180 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment Angiographic Binary Restenosis rate</measure>
    <time_frame>at 180 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting incomplete apposition, late incomplete apposition, aneurysm, thrombus, persisting dissection</measure>
    <time_frame>at 180 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>at 30, 180, 270 days, and 1, 2, 3, 4, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>at 30, 180, 270 days, and 1, 2, 3, 4, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success (device, procedure and clinical)</measure>
    <time_frame>Acute</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Everolimus</condition>
  <condition>Vascular Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abbott Vascular MULTI-LINK VISION® BMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary artery drug eluting stent placement</intervention_name>
    <description>Coronary artery drug eluting stent placement</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary artery stent placement</intervention_name>
    <description>Coronary artery stent placement</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Abbott Vascular MULTI-LINK VISION® coronary stent system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patient must be at least 18 years of age.&#xD;
&#xD;
          2. Patient is able to verbally acknowledge an understanding of the associated risks,&#xD;
             benefits and treatment alternatives of receiving the XIENCE™ V Everolimus Eluting&#xD;
             Coronary Stent System and his or her legally authorized representative provides&#xD;
             written informed consent prior to the stent procedure, as approved by the appropriate&#xD;
             Ethics Committee.&#xD;
&#xD;
          3. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,&#xD;
             silent ischemia, positive functional study).&#xD;
&#xD;
          4. Patient must be an acceptable candidate for coronary artery bypass graft (CABG)&#xD;
             surgery.&#xD;
&#xD;
          5. Patient must agree to undergo all protocol-required follow-up examinations including&#xD;
             angiographic and IVUS follow-up at two time points (180 days and 1 year ).&#xD;
&#xD;
          6. Female patients of childbearing potential must have had a negative pregnancy test&#xD;
             within 7 days before treatment, and must not be nursing at the time of treatment.&#xD;
&#xD;
          7. Female patients of childbearing potential must also agree at time of consent to use&#xD;
             birth control up to and including the second angiographic follow-up at 1 year.&#xD;
&#xD;
        Inclusion Criteria: Angiographic&#xD;
&#xD;
          1. Planned single, de novo, type A - B1, native coronary artery lesion treatment.&#xD;
&#xD;
          2. Target lesion must be located in a native vessel with a diameter of 3.0 mm assessed by&#xD;
             QCA on-line.&#xD;
&#xD;
          3. Target lesion length ≤ 12 mm, assessed by QCA on-line.&#xD;
&#xD;
          4. The target lesion must be in a major artery or branch with a stenosis of ≥ 50% and &lt;&#xD;
             100% assessed by QCA on-line and with a TIMI flow of ≥ 1.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patient has had a known acute myocardial infarction (greater than two times the upper&#xD;
             limit of normal CK with presence of CK-MB) within 3 days preceding the index procedure&#xD;
             and CK has not returned to normal limits at the time of the procedure.&#xD;
&#xD;
          2. Patient has current or a history of unstable arrhythmias, regardless of whether&#xD;
             cardiac rhythm management devices are used (e.g., pacemaker, Automatic Implantable&#xD;
             Cardioverter Defibrillator).&#xD;
&#xD;
          3. Patient has a known left ventricular ejection fraction ≥ 30%.&#xD;
&#xD;
          4. Patient has received a heart transplant or any other organ transplant or is on a&#xD;
             waiting list for any organ transplant.&#xD;
&#xD;
          5. Patient is receiving or scheduled to receive chemotherapy or radiation therapy within&#xD;
             30 days prior to or after the procedure.&#xD;
&#xD;
          6. Patient is receiving immunosuppression therapy or has known immunosuppressive disease.&#xD;
&#xD;
          7. Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).&#xD;
&#xD;
          8. Patient has a known hypersensitivity or contraindication to aspirin, heparin,&#xD;
             clopidogrel, cobalt, chromium, nickel, tungsten, everolimus, acrylic and fluoro&#xD;
             polymers or contrast sensitivity that cannot be adequately pre-medicated.&#xD;
&#xD;
          9. Patient has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, a WBC of &lt;3,000&#xD;
             cells/mm3, or documented or suspected liver disease (including laboratory evidence of&#xD;
             hepatitis).&#xD;
&#xD;
         10. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5&#xD;
             mg/dL, patient on dialysis).&#xD;
&#xD;
         11. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions.&#xD;
&#xD;
         12. Patient has had a cerebrovascular accident (CVA) or stroke or transient ischemic&#xD;
             neurological attack (TIA) within the past six months.&#xD;
&#xD;
         13. Patient has had a significant GI or urinary bleed within the past six months.&#xD;
&#xD;
         14. Patient has extensive peripheral vascular disease that precludes safe 6 French sheath&#xD;
             insertion or extreme anticoagulation.&#xD;
&#xD;
         15. Patient has other medical illness (e.g., cancer or congestive heart failure) or recent&#xD;
             history of substance abuse that may cause non-compliance with the protocol, confound&#xD;
             the data interpretation or is associated with a limited life expectancy (i.e., less&#xD;
             than one year).&#xD;
&#xD;
         16. Patient is already participating in another investigational use device or drug study&#xD;
             or has completed the follow-up phase of another trial within the last 30 days.&#xD;
&#xD;
         17. Patient has received a drug eluting stent within the last 1 year.&#xD;
&#xD;
        Exclusion Criteria: Angiographic&#xD;
&#xD;
          1. The target lesion meets any of the following criteria:&#xD;
&#xD;
               1. Aorto-ostial location&#xD;
&#xD;
               2. Unprotected left main location&#xD;
&#xD;
               3. Located within 2 mm of the origin of the LAD or LCX&#xD;
&#xD;
               4. Located within or distal to an arterial or saphenous vein graft&#xD;
&#xD;
               5. Located within 2 mm of a bifurcation&#xD;
&#xD;
               6. Located distal to a previously implanted stent (same major epicardial vessel)&#xD;
&#xD;
               7. Located in a major epicardial vessel that has been previously treated with&#xD;
                  brachytherapy&#xD;
&#xD;
               8. Located in a major epicardial vessel that has been previously treated with any&#xD;
                  type of PCI (e.g., POBA, stent, cutting balloon, atherectomy), except if previous&#xD;
                  treatment occurred in a side branch distal to target lesion at least 180 days&#xD;
                  preceding the index procedure&#xD;
&#xD;
               9. Involves jailing of side branches &gt; 2.0 mm in diameter&#xD;
&#xD;
              10. Total occlusion (TIMI flow 0)&#xD;
&#xD;
              11. Excessive tortuosity proximal to or within the lesion&#xD;
&#xD;
              12. Extreme angulation (≥ 90%) proximal to or within the lesion&#xD;
&#xD;
              13. Moderate to heavy calcification&#xD;
&#xD;
              14. Restenotic from previous intervention&#xD;
&#xD;
          2. The target vessel contains thrombus.&#xD;
&#xD;
          3. Another significant lesion (≥ 40 %DS) is located in the same major epicardial vessel&#xD;
             as the target lesion.&#xD;
&#xD;
          4. Patient has a high probability that a procedure other than pre-dilatation and stenting&#xD;
             will be required for treatment of the target vessel (e.g. atherectomy, cutting&#xD;
             balloon).&#xD;
&#xD;
          5. Patient has additional lesion(s) for which an intervention within 180 days (prior to&#xD;
             or after) of the index procedure would be required or has been performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Serruys, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Siegburg GmbH</name>
      <address>
        <city>Siegburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://eurheartj.oxfordjournals.org/cgi/content/abstract/28/13/1583</url>
    <description>Clinical impact of in-stent late loss after drug-eluting coronary stent implantation</description>
  </link>
  <reference>
    <citation>Tsuchida K, García-García HM, Ong AT, Valgimigli M, Aoki J, Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PW. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv. 2006 Feb;67(2):188-97.</citation>
    <PMID>16400664</PMID>
  </reference>
  <results_reference>
    <citation>Popma JJ, Tulli M. Spirit First - Another hurdle is cleared. EuroIntervention. 2005 Nov;1(3):260-3.</citation>
    <PMID>19758913</PMID>
  </results_reference>
  <results_reference>
    <citation>Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2005 May;1(1):58-65.</citation>
    <PMID>19758878</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention. 2005 Nov;1(3):266-72.</citation>
    <PMID>19758915</PMID>
  </results_reference>
  <results_reference>
    <citation>Beijk MA, Neumann FJ, Wiemer M, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys PW, Piek JJ. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). EuroIntervention. 2007 Aug;3(2):206-12.</citation>
    <PMID>19758939</PMID>
  </results_reference>
  <results_reference>
    <citation>SPRITI FIRST: 2-Jahres-ergebnisse. A durable polymer everolimus-eluting stent in de novo coronary narrowings. Richartz B.; Silber S. Herz ( Germany ) June 1, 2006 , 31/4 (359). ISSN: 0340-9937. Language: German</citation>
  </results_reference>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>January 5, 2010</last_update_submitted>
  <last_update_submitted_qc>January 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Matt Kiely</name_title>
    <organization>Abbott Vascular</organization>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

